 HOOKIPA Pharma Inc NASDAQ: HOOK has announced preclinical data demonstrating potent T cell responses, combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers. Preclinical data show that combining co-. 